SCHEMBL8320346

SCHEMBL8320346

O=C(O)c1cccc(-c2c[nH]c3ncc(-c4ccccc4Oc4ccccc4)cc23)c1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMKK2 Q96RR4 4/20 0.83
AXL P30530 7/20 0.72
IGF1R P08069 6/20 0.70
SGK1 O00141 1/20 0.59
NEK1 Q96PY6 2/20 0.58
CDC7 O00311 1/20 0.57
PLK4 O00444 1/20 0.57
CHEK1 O14757 1/20 0.57
AURKA O14965 1/20 0.57
MAPK13 O15264 1/20 0.57
PDPK1 O15530 1/20 0.57
DYRK3 O43781 1/20 0.57
ROCK2 O75116 1/20 0.57
RPS6KA5 O75582 1/20 0.57
PRKD3 O94806 1/20 0.57
PAK4 O96013 1/20 0.57
CHEK2 O96017 1/20 0.57
ABL1 P00519 1/20 0.57
EGFR P00533 1/20 0.57
NTRK1 P04629 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13745445 0.91 CAMKK2 (1.00) CAMKK2AXLIGF1RSGK1NEK1
SCHEMBL13745640 0.90 CAMKK2 (0.67) CAMKK2AXLIGF1RNEK1CDC7
SCHEMBL13745434 0.89 CAMKK2 (0.69) CAMKK2AXLIGF1RDYRK3ROCK2
SCHEMBL1487600 0.88 CAMKK2 (0.79) CAMKK2AXLIGF1RPLK4AURKA
SCHEMBL13753939 0.87 CAMKK2 (0.69) CAMKK2AXLIGF1RRIPK1
SCHEMBL13746980 0.87 CAMKK2 (0.64) CAMKK2AXLIGF1RNEK1DYRK3
SCHEMBL13746383 0.87 CAMKK2 (0.64) CAMKK2AXLIGF1RNEK1DYRK3
SCHEMBL13746111 0.87 CAMKK2 (0.64) CAMKK2AXLIGF1RNEK1DYRK3
SCHEMBL13745636 0.87 CAMKK2 (0.69) CAMKK2AXLIGF1RNEK1CDC7
SCHEMBL13745437 0.87 CAMKK2 (0.66) CAMKK2AXLIGF1RNEK1DYRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
WO-2004078756-A2 JNK INHIBITORS EISAI CO., LTD. (JP) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215771-A1 JNK INHIBITORS MAPKAPK2, MAPK1, MAPKAPK3 CAMKK2 94/4885AXL 3999/4885IGF1R 1197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.